arotid artery stenting was developed as an alternative to endarterectomy for the management of patients with carotid stenosis in the 1990s. With the assumption that an endovascular approach would offer a more favorable safety profile than an open surgical procedure, the use of stenting increased significantly 1 after its entry into the market. In the United States, the use of stenting increased from 3% of patients undergoing carotid artery revascularization procedures in 1998 to 13% in 2008.
applied a modified version of the McMaster RCT Hedge filter to optimize sensitivity and specificity 5 to restrict our search to RCTs. In addition, in these databases, we restricted our search to articles published in English or French. Finally, we manually searched the bibliographies of previous systematic reviews and relevant trials to retrieve additional RCTs and updates of already included RCTs that were not identified in our electronic search.
Study Selection
We included RCTs that compared stenting with endarterectomy among patients with symptomatic or asymptomatic carotid stenosis. Inclusion was restricted to RCTs reporting any of the following periprocedural or long-term outcomes: any stroke (including disabling or major stroke and nondisabling or minor stroke), hematoma, cranial nerve palsy, myocardial infarction (MI), or death. Furthermore, to minimize the potential effects of publication bias, 6 we restricted inclusion to RCTs that randomized ≥50 patients. We excluded RCTs in which both randomized groups did not have an equal opportunity to receive antiplatelet or anticoagulant therapies. There were no restrictions on the use of embolic-protection devices (EPD). We contacted the authors of potentially relevant RCTs to clarify ambiguities on eligibility and to request relevant unpublished data.
We excluded observational studies (eg, cohort, cross-sectional, or case-control), systematic reviews and meta-analyses, case reports and case series, as well as letters to the editor, editorials, reviews, and commentaries. We also excluded abstracts from conference proceedings because their results are often not final and they contain insufficient information to thoroughly assess study quality. In addition, RCTs published in a language other than English or French were not considered. Finally, basic science and studies performed on animal models were also excluded.
Data Extraction
Two independent reviewers extracted data using a standardized, pilot-tested data extraction form, with disagreements resolved by consensus or when necessary, a third reviewer. For each included RCT, we extracted the following study characteristics: year of publication, inclusion and exclusion criteria, recruitment period, total number of randomized patients, median length of follow-up, the proportion of symptomatic patients, the median time from randomization to intervention, and the use of EPD. We also extracted the following baseline demographic and clinical characteristics: age, sex, vascular risk factors, degree of stenosis at randomization, and medication use before randomization. Outcomes of interest included any periprocedural and long-term stroke, MI, hematoma, cranial nerve palsy, and death. Long-term outcomes included all postprocedural events, including those that occurred during the periprocedural period. For all outcomes, count data and hazard ratios with their corresponding 95% confidence intervals (CIs) were extracted. Where available, we collected information on the following subgroups: younger or older patients (using the age categories reported by the individual trials), men or women, and symptomatic or asymptomatic patients.
Quality Assessment
We evaluated the quality of each included RCT using the Cochrane Collaboration's tool for assessing risk of bias. 7 More specifically, we evaluated each RCT's sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias. The role of the funding source was also considered. For each domain, 2 independent reviewers assigned a score of high, low, or unclear risk of bias, with disagreements resolved by consensus or a third reviewer.
Statistical Analysis
Using count data, we estimated relative risks (RRs) and their corresponding 95% CIs for periprocedural and long-term outcomes in patients randomized to stenting when compared with those in patients randomized to endarterectomy using DerSimonian and Laird random-effects models 8 with inverse-variance weighting. We also estimated the risk difference for the outcomes of stroke and MI in the periprocedural period. We used a 0.5 continuity correction to allow for the inclusion of data from RCTs with no events. To estimate the amount of heterogeneity between the RCTs, we calculated I 2 values. 9 We also conducted several subgroup and sensitivity analyses. Stratified analyses were performed using the composite end point of long-term ipsilateral stroke, periprocedural stroke, or periprocedural death based on the following subgroups: age, sex, and symptomatic status. To examine the effect of study-level covariates on our treatment estimates, univariate metaregression analyses were performed. Covariates examined were the proportion of women, the proportion of EPD use, median length of follow-up, median calendar year of the recruitment period, the presence of minimum operator experience requirements, the proportion of symptomatic patients, and the proportion of older patients. We also examined the effect of EPD on perioperative stroke outcomes by patient risk category (low versus high). In sensitivity analyses, we repeated our meta-analyses using fixed-effects models with inverse-variance weighting. In addition, we conducted influence analyses to examine the influence of each individual RCT on our overall treatment effects for the outcome of any long-term stroke, as this outcome was reported by the greatest number of RCTs. We then repeated our influence analyses using the composite end point of long-term ipsilateral stroke, periprocedural stroke, or periprocedural death, the primary stroke outcome of the present study. All the statistical analyses were performed using the meta and metafor packages of R version 3. 
Results

Search Results
Our electronic search identified 2006 potentially relevant publications ( Figure 1 ). After excluding duplicates and screening titles and abstracts, we retrieved 68 publications for full-text review. Of these, 16 reports 10-25 of 8 RCTs met our inclusion criteria. One additional publication presenting the long-term results of an already included RCT was identified through our correspondence with authors and was published during the conduct of our meta-analysis. 26 
WHAT IS KNOWN
• Carotid endarterectomy and stenting are 2 commonly used techniques to treat carotid stenosis.
• Current guidelines recommend the use of endarterectomy for patients with severe symptomatic carotid stenosis and a low risk of perioperative stroke or death.
WHAT THE STUDY ADDS
• 24 and asymptomatic patients for the second part; these 2 study populations were merged in a single analysis of long-term follow-up data. 22 All RCTs used stents in the endovascular arm except the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVA-TAS), which used balloon angioplasty before 1994 and stenting at the operator's discretion thereafter. 18 CAVATAS, Brooks et al, and Steinbauer et al did not use EPD, whereas the other 5 trials did (Appendix V in the Data Supplement). Five trials 10, 12, 14, 17, 20 required a minimum amount of operator experience to participate in the trial. The median follow-up durations ranged from 2.0 to 10.0 years.
Overall, populations were relatively similar (Appendix VI in the Data Supplement). Mean ages ranged from 68.1 to 72.6 years, and most trials had >62% of patients with ≥70% ipsilateral carotid stenosis. The Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial was the only trial for which the majority of randomized patients were asymptomatic, and it exclusively targeted patients at high surgical risk. 20 
Quality Assessment
Most included trials were of high quality (Appendix VII in the Data Supplement). However, 3 trials were stopped prematurely: 1 for safety and futility, 16 1 for futility and cost, 13 and 1 because of a sudden decrease in enrolment rate. 20 These trials were, therefore, assigned an unclear evaluation for the other risk of bias domain. In addition to stopping prematurely, SAPPHIRE had greater losses to follow-up among patients randomized to endarterectomy than among those randomized to stenting (29.9% versus 14.4%, respectively), 20 resulting in a potential selection bias and a high risk for this domain. Importantly, 2 trials 22, 25 did not report the proportion lost-to-followup by treatment group; however, the overall proportions were relatively low, suggesting a low risk of bias.
Periprocedural Outcomes
During the periprocedural period, defined in most studies as the 30 days after the intervention, stenting was associated with a higher risk of stroke outcomes (Table 2) . When data were pooled across trials, stenting was associated with a significantly higher risk of any stroke (RR, 1.49; 95% CI, 1.11-2.01; Appendix VIII in the Data Supplement). However, results 
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October 2015 from individual trials suggest that much of this increase was because of a higher incidence of periprocedural nondisabling or minor strokes in the stenting arm (eg, 6.1% versus 2.3% in Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis [EVA-3S]). The risks of periprocedural disabling or major stroke were similar between treatment arms (Table 2) . Heterogeneity in the definitions of disabling or major strokes prevented the pooling of these data across trials. Stenting had a higher incidence of a composite outcome of periprocedural stroke or death in most trials. When data were pooled across trials, stenting was associated with a significantly higher risk of this composite end point (RR, 1.50; 95% CI, 1.12-2.02; Appendix IX in the Data Supplement).
When data were pooled across trials, stenting was associated with a significantly lower risk of MI in the periprocedural period (RR, 0.47; 95% CI, 0.29, 0.78; Figure 2 ). In addition, stenting was associated with decreased risks in surgically related adverse outcomes, such as severe hematoma (RR, 0.35; 95% CI, 0.21-0.57; Appendix X in the Data Supplement) and cranial nerve palsy (RR, 0.08; 95% CI, 0.04-0.14; Appendix XI in the Data Supplement). Available data also suggest that stenting may be associated with an increased risk of bradycardia, hypotension, and restenosis although heterogeneity prevented the pooling of these data across trials (Appendix XII in the Data Supplement).
To better understand the trade-off between periprocedural MI and stroke among patients undergoing stenting, pooled risk differences were calculated for these outcomes. Overall, we found that stenting was associated with a 0.4% decreased risk of MI and a 1.7% increased risk of stroke. When excluding the high surgical risk patient population from SAPPHIRE, a 0.3% decreased risk of MI and a 1.8% increased risk of stroke were obtained (Appendices XIII and XIV in the Data Supplement).
Long-Term Outcomes
During long-term follow-up, the cumulative incidence of any stroke varied across trials, ranging from 8.3% in the stenting arm and 6.0% in the endarterectomy arm of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), the largest trial, to 26.7% and 19.0%, respectively, in CAVA-TAS (Table 3) . When data were pooled across trials, the risk of any long-term stroke was significantly higher with stenting than with endarterectomy (RR, 1.36; 95% CI, 1.16-1.61; Figure 3) .
Stenting was also associated with a significantly increased risk of long-term ipsilateral stroke (including periprocedural stroke or death) when compared with endarterectomy in the 6 trials that reported this composite end point (RR, 1.45; 95% ‡A total of 20 patients were excluded from the analysis because of scientific misconduct. §Symptomatic patients with ≥50% carotid stenosis on angiography, ≥70% stenosis on U/S, or ≥70% stenosis on CT scan or MRI if 50% to 69% stenosis on U/S. ||Asymptomatic patients with ≥60% carotid stenosis on angiography, ≥70% stenosis on U/S, and ≥80% stenosis on CT or on MRI. ¶Length of follow-up reported for cumulative incidence. #Single-center trial. **Brooks et al 22 is a long-term follow-up study of the combined populations presented separately in Brooks et al 24 and Brooks et al. 23 The total number of patients included in the intention-to-treat analysis is 189 (85 asymptomatic patients from Brooks et al 24 and 104 symptomatic patients from Brooks et al 23 )
.
CI, 1.20-1.75; Figure 4 ). CAVATAS did not include periprocedural stroke or death as a part of their ipsilateral stroke end point, and SAPPHIRE did not report a composite of long-term ipsilateral stroke or periprocedural stroke or death. However, CAVATAS investigators have previously examined ipsilateral strokes outside of the periprocedural period and found an increased risk with stenting although the estimate was accompanied by a wide 95% CI (hazard ratio, 1.22; 95% CI, 0.59-2.54).
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The long-term incidence of disabling or major stroke was also higher with stenting in all trials that reported this outcome except SAPPHIRE (Table 3) . SAPPHIRE was the only trial to report major ipsilateral stroke data (ie, excluding all major nonipsilateral strokes). Trial-specific results for this outcome were inconclusive, and heterogeneity in the definition of the composite end point of disabling and major stroke prevented the pooling these data across trials.
Subgroup and Metaregression Analyses
In prespecified subgroup analyses, we found a significantly increased risk of long-term stroke among older patients in the stenting arm (RR, 1.54; 95% CI, 1.20-1.98) but no increased *The periprocedural period is within 30 days of the procedure for most trials. In CREST and SPACE, it includes the time between randomization and 30 days post procedure. ICSS defines the periprocedural period as the 120 days after randomization, provided that all patients received the procedure within 3 months.
†Table is presented in decreasing order of the total number of randomized patients. ‡Defined as a modified Rankin Scale score of ≥3 or the need for assistance for >30 days as a result of stroke. §Disabling stroke includes major ipsilateral and major nonipsilateral stroke, with major defined on the basis of clinical data or an NIHSS score of ≥9 in the 90 days after the procedure.
||Only ipsilateral disabling stroke reported. ¶Any stroke lasting >7 days. #Only nonfatal MI reported. **Disabling stroke includes major ipsilateral and major nonipsilateral stroke, with major defined according to NIHSS score, Barthel index, and modified Rankin Scale score. risk among younger patients (RR, 1.01; 95% CI, 0.56-1.81; Appendix XV in the Data Supplement). Our subgroup analyses stratified by sex and symptomatic status revealed no important differences (Appendices XVI-XIX in the Data Supplement). Similarly, none of the trial-level characteristics examined via metaregression had an important impact on the magnitude of the observed treatment effects (Appendix XX in the Data Supplement). In addition, with only 1 trial conducted in high-risk patients, available data were insufficient to determine whether the efficacy of EPD to prevent perioperative stroke differed with patient risk (Appendix XXI in the Data Supplement).
Sensitivity Analysis
We repeated our primary analyses with fixed-effects models with inverse-variance weighting (Appendix XXII in the Data Supplement). These analyses produced results that were similar to those of our primary analyses. In addition, we conducted an influence analysis to evaluate the influence of individual trials on our overall results for the outcome of any long-term stroke. This analysis revealed that no individual trial had a particularly strong influence on our results, with estimates ranging from an RR of 1.29 to 1.43, all with 95% CIs excluding unity (Appendix XXIII in the Data Supplement). Similar results were obtained when using the composite end point of Table 2 for sample sizes). †Includes long-term major ipsilateral stroke or any major periprocedural stroke. ‡Length of follow-up reported for cumulative incidence. §Ipsilateral ischemic strokes only. ||Includes long-term ipsilateral disabling stroke or periprocedural disabling stroke or death. ¶Includes periprocedural nonstroke death. #Includes long-term stroke lasting >7 days or any periprocedural stroke (ie, including stroke of >7 or <7 days). **Only nonprocedural ipsilateral stroke reported (CAS=12; CEA=11; HR=1.22, 95% CI=0.59-2.54). † †Major ipsilateral strokes only. ‡ ‡Ipsilateral stroke only. long-term ipsilateral stroke, periprocedural stroke, or periprocedural death (data not shown).
Discussion
Our study was designed to examine the safety and efficacy of stenting when compared with those of endarterectomy in patients with carotid stenosis, with a particular focus on longterm outcomes. We found that stenting was associated with a decreased risk of periprocedural MI, hematoma, and cranial nerve palsy, but with an increased risk of most periprocedural stroke outcomes. Furthermore, the increased risk of stroke and an increased risk of a composite end point of ipsilateral stroke, periprocedural stroke, or periprocedural death persisted throughout follow-up. These results suggest that endarterectomy has more favorable effects on periprocedural and long-term outcomes and should remain the treatment of choice for patients with carotid stenosis. Although our periprocedural results are similar to those of previous studies, [27] [28] [29] to our knowledge, our meta-analysis is the first to include the long-term results from Brooks et al, 22 EVA-3S, 15 and the International Carotid Stenting Study (ICSS). 26 With the inclusion of these recently available data, our meta-analysis has produced more precise estimates than those of previous studies in this area, including a previous Cochrane review by Bonati et al 30 (odds ratio for long-term stroke and periprocedural death, 1.39; 95% CI, 1.10-1.75). Importantly, the higher cumulative incidence in strokerelated events throughout follow-up seems to be driven by an increased risk during the periprocedural period; Bonati et al 30 found no increase in the incidence of ipsilateral stroke during follow-up when periprocedural events were excluded from the analysis (odds ratio, 0.93; 95% CI, 0.60-1.45). 30 The exclusion of such events suggests that stenting and endarterectomy are comparable in terms of postprocedural stroke rate, but the inclusion of such events is crucial when evaluating the overall safety and efficacy of these interventions.
Although the presence of important heterogeneity in outcome definitions prevented the meta-analysis of stroke outcomes by severity, available data suggest that the observed increased risk of periprocedural stroke seems to be driven by an increased risk of nondisabling or minor stroke, with a comparable risk of disabling or major stroke between the groups. This pattern was consistently observed among the individual trials included in the present meta-analysis.
The observed reduction in periprocedural MI, hematoma, and cranial nerve palsy with stenting also warrants some discussion. Despite its statistical significance, the absolute difference in MI remains small; stenting was associated with a 0.4% decreased risk of MI when compared with a 1.7% increased risk of stroke when data were pooled across all trials. The trade-off between MI and stroke becomes more apparent when analyses are stratified by surgical risk. In SAPPHIRE, which was conducted in patients with at least 2 surgical risk factors, stenting was associated with a 3.6% decreased risk of MI versus a 0.6% increased risk of stroke. In contrast, in analyses restricted to the low surgical risk patients included in the other trials, stenting resulted in a 0.3% decreased risk of MI and a 1.8% increased risk of stroke. The relative importance of such events is well illustrated via their impact on healthrelated quality of life; in a CREST substudy, periprocedural MI was not associated with a poorer health-related quality of life at 1 year, whereas periprocedural stroke was associated with a substantial decrease in health-related quality of life. 31 Thus, although the trade-off of decreased risk of MI versus increased risk of stroke clearly favors endarterectomy both in patients with carotid stenosis overall and in low-risk patients, it is less clear among high-risk patients.
The importance of patients' underlying procedural risk has been incorporated in the 2011 updated Society of Vascular Surgery guidelines for the management of carotid stenosis. 3 Although these guidelines generally recommend endarterectomy over stenting in symptomatic patients, they recommend that the risk of perioperative stroke or death should be <3% for endarterectomy to be considered beneficial in asymptomatic patients. 3 Although the available data provide strong evidence on an increased risk of stroke with stenting, much of this evidence is derived from symptomatic patients. Although we did not identify differences in treatment effects between symptomatic and asymptomatic patients in our subgroup analysis, some uncertainty remains on the potential use of stenting in asymptomatic patients. 32 Ongoing trials restricted to this patient population 33 which started in December 2014, will help further clarify outcomes of carotid endarterectomy, carotid stenting, and medical therapy among patients with carotid artery stenosis.
Our subgroup analyses revealed important differences in treatment effects across age groups, with older patients having an increased risk of stroke in the stenting arm. This finding is consistent with that of a recent meta-analysis of outcomes after stenting and endarterectomy in elderly patients 34 and may be explained by the increased calcification and tortuosity of the supra-aortic branches in older patients. [35] [36] [37] Although the results of CREST suggest a possible benefit with stenting in patients aged <70 years old, 10 no difference in stroke rate was observed in younger patients when data were pooled across trials. 3 Some trials have also suggested that treatment effects may differ in men and women, 11, 38, 39 and there is currently no consensus for management of carotid stenosis in women. [40] [41] [42] For this reason, we conducted prespecified, sex-specific subgroup analyses, which revealed no important differences in treatment effects between sexes. Consequently, it is possible that the previously reported sex differences were chance findings. Nonetheless, additional studies are required to better understand the influence of sex on the safety and efficacy of stenting and endarterectomy.
Although our metaregression models did not find any important impact on the observed outcomes from the use of EPD, only distal filter EPDs were used in included studies. We were thus unable to examine the efficacy of newer proximal EPDs. However, a recent study of 10 246 consecutive elective CAS procedures performed with embolic protection in the National Cardiovascular Data Registry Carotid Artery Revascularization and Endarterectomy program found that proximal and distal filter EPDs had similar rates of adverse events. 43 In addition, with only 8 included trials and only 1 trial conducted in high-risk patients, there were insufficient data to explicitly examine the interaction between risk profile and EPD efficacy.
Limitations
Our study had several potential limitations. First, heterogeneity was present among RCTs with respect to duration of follow-up, patient recruitment periods, types of stents used, minimal operator requirements for participation, use of EPDs, and patient characteristics. Despite this, results were generally consistent across trials. Furthermore, we used random-effects models to account for between-study heterogeneity, and our metaregression results suggest that treatment effects did not vary with trial characteristics. Examined trial characteristics included duration of follow-up, which ranged from 2 to 10 years. The null finding in this metaregression analysis suggests that treatment effects do not differ over time, with RRs consistent across the durations of follow-up examined. Heterogeneity in some outcome definitions (eg, major and disabling stroke) prevented the pooling of these data. For this reason, these data were qualitatively synthesized via systematic review.
Second, our systematic search of the literature was limited to the articles indexed on or before October 22, 2014, including the long-term outcomes of ICSS. 26 To ensure that no additional relevant RCTs were published since that time, 1 author (S.V.) screened all potentially relevant publications published between the date of our literature search and June 2015; this search revealed no additional studies that met our inclusion criteria. Our flow diagram was not updated to reflect this revised search as the update was only conducted by 1 reviewer.
Third, we excluded 3 small trials [44] [45] [46] included in previous meta-analyses. 27, 47 These trials randomized 23, 20, and 40 patients, respectively. Although 1 was suspended, 44 the others found no significant difference in outcomes between carotid endarterectomy and stenting. 45, 46 With >7000 patients randomized in the 8 included trials, the inclusion of these 3 small trials (total sample size = 83) would have had a minimal impact on our results. Our minimum sample size requirement was included to decrease the potential effects of publication bias, which occurs because small studies are more likely to be published if their findings are statistically significant. 6 Although this decision may have modestly decreased the precision of our results, the exclusion of such studies likely resulted in more valid treatment estimates.
Finally, with 8 included trials and several different stents used, we were unable to conduct subgroup analyses by type of stent or by all patient characteristics. Nonetheless, we conducted subgroup and metaregression analyses for several study and patient characteristics.
Conclusions
Our study was designed to examine the safety and efficacy of stenting compared with endarterectomy in patients with carotid stenosis, with a particular focus on long-term outcomes. Although stenting had more favorable periprocedural outcomes with respect to MI, hematoma, and cranial nerve palsy, endarterectomy had more favorable periprocedural stroke outcomes. With the observed increased risk of stroke persisting throughout follow-up with stenting, available data suggest that endarterectomy remains the treatment of choice for the management of carotid stenosis.
